Hal Barron, GSK R&D chief (UKBIO19)
Hal Barron’s swan song at GSK: An ‘exceptional’ legacy, thoughts on risk and a singular decision-making model
With booming Shingrix sales filling its financial sails in the wake of the Haleon spinout, the executive team at New GSK repeatedly touted the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
